Screener
Summit Therapeutics SMMT Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Fair Value Hierarchy Level | March 31, 2026 / Amortized Cost | March 31, 2026 / Unrealized Gain | March 31, 2026 / Unrealized (Loss) | March 31, 2026 / Credit (Loss) | March 31, 2026 / Fair Value |
|---|---|---|---|---|---|---|
| Financial assets included within cash and cash equivalents: | ||||||
| Money market funds | Level 1 | $98,277 | — | — | — | $98,277 |
| Financial assets included within short-term investments: | ||||||
| Certificate of deposit | Level 2 | 25,000 | — | — | — | 25,000 |
| U.S. Government treasury bills | Level 2 | 467,220 | — | (4) | — | 467,216 |
| Total | $590,497 | — | $(4) | — | $590,493 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's unrealized gains on investments?
- Summit Therapeutics (SMMT) reported unrealized gains on investments of $0 in Q1 2026.
- What is the long-term trend for Summit Therapeutics's unrealized gains on investments?
- Over 2 years (2023 to 2025), Summit Therapeutics's unrealized gains on investments has grown at a 118.6% compound annual growth rate (CAGR), from $36K to $172K.
Ask your AI about Summit Therapeutics's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude